BiotechTube
Taysha Gene Therapies

Taysha Gene Therapies

TSHA
United States

Taysha Gene Therapies is dedicated to eradicating monogenic CNS diseases through intrathecal delivery of gene therapies. The company has built a robust pipeline leveraging academic partnerships, most notably with UT Southwestern's Gene Therapy Program, and has advanced multiple candidates into clinical development. Following a strategic refocusing in 2023, Taysha is prioritizing its most promising assets, TSHA-102 for Rett syndrome and TSHA-120 for GAN, while seeking partnerships for earlier-stage programs. Its mission centers on addressing the high unmet need in rare neurological diseases with single-administration curative potential.

tayshagtx.com

TSHA · Stock Price

USD 4.13+2.33 (+129.44%)
Market Cap: $1.3B

Historical price data

AI Company Overview

Taysha Gene Therapies is dedicated to eradicating monogenic CNS diseases through intrathecal delivery of gene therapies. The company has built a robust pipeline leveraging academic partnerships, most notably with UT Southwestern's Gene Therapy Program, and has advanced multiple candidates into clinical development. Following a strategic refocusing in 2023, Taysha is prioritizing its most promising assets, TSHA-102 for Rett syndrome and TSHA-120 for GAN, while seeking partnerships for earlier-stage programs. Its mission centers on addressing the high unmet need in rare neurological diseases with single-administration curative potential.

NeurologyRare DiseasesGenetic Disorders

Technology Platform

AAV9-based gene therapy platform focused on intrathecal delivery for central nervous system disorders, featuring a microRNA-responsive auto-regulatory element (miRARE) for controlled transgene expression.

Pipeline

1
1 drug in pipeline
DrugIndicationStageWatch
TSHA-101Infantile GM2 Gangliosidosis (Disorder)Phase 1/2

Funding History

3
Total raised:$275.5M
IPO$150.5MSep 15, 2020
Series B$95MJun 15, 2020
Series A$30MDec 15, 2019

Opportunities

Taysha's primary growth opportunities lie in successfully demonstrating clinical proof-of-concept for its lead programs in Rett syndrome and GAN, which could unlock significant value and partnership interest.
The company's deep preclinical pipeline in other monogenic CNS disorders represents additional future value drivers, potentially through strategic partnerships or out-licensing deals.

Risk Factors

Key risks include clinical trial failures, the inherent challenges of gene therapy development (safety, durability, manufacturing), a constrained financial runway requiring future capital raises, and intense competition in the neurology and gene therapy spaces.
Regulatory hurdles for novel CNS gene therapies also pose a significant risk.

Competitive Landscape

Taysha competes with other companies developing therapies for Rett syndrome (e.g., Acadia/Neuren) and GAN, as well as broader CNS gene therapy platforms from companies like Neurogene, Novartis, and Sarepta. Its differentiation is its focused expertise in intrathecal AAV9 delivery for monogenic diseases and its proprietary miRARE technology for expression control.